IL164921A0 - Synergistic interaction of abacavir and alovudine - Google Patents
Synergistic interaction of abacavir and alovudineInfo
- Publication number
- IL164921A0 IL164921A0 IL16492104A IL16492104A IL164921A0 IL 164921 A0 IL164921 A0 IL 164921A0 IL 16492104 A IL16492104 A IL 16492104A IL 16492104 A IL16492104 A IL 16492104A IL 164921 A0 IL164921 A0 IL 164921A0
- Authority
- IL
- Israel
- Prior art keywords
- alovudine
- abacavir
- synergistic interaction
- treatment
- combined
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- AIDS & HIV (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Mechanical Treatment Of Semiconductor (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0202022A SE0202022D0 (sv) | 2002-06-27 | 2002-06-27 | Synergistic interaction of abacavir and alovudine |
EP02024744 | 2002-11-06 | ||
PCT/SE2003/001100 WO2004002433A1 (en) | 2002-06-27 | 2003-06-24 | Synergistic interaction of abacavir and alovudine |
Publications (1)
Publication Number | Publication Date |
---|---|
IL164921A0 true IL164921A0 (en) | 2005-12-18 |
Family
ID=30001852
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL16492104A IL164921A0 (en) | 2002-06-27 | 2004-10-28 | Synergistic interaction of abacavir and alovudine |
Country Status (19)
Country | Link |
---|---|
US (1) | US20060084627A1 (xx) |
EP (1) | EP1536800B1 (xx) |
JP (1) | JP2005533870A (xx) |
KR (1) | KR20050013628A (xx) |
CN (1) | CN1302779C (xx) |
AT (1) | ATE314851T1 (xx) |
AU (1) | AU2003239088B2 (xx) |
BR (1) | BR0311141A (xx) |
CA (1) | CA2481890A1 (xx) |
DE (1) | DE60303131T2 (xx) |
ES (1) | ES2254941T3 (xx) |
HK (1) | HK1079981B (xx) |
IL (1) | IL164921A0 (xx) |
MX (1) | MXPA04012754A (xx) |
NO (1) | NO20050445L (xx) |
NZ (1) | NZ535817A (xx) |
PL (1) | PL373758A1 (xx) |
RU (1) | RU2320347C2 (xx) |
WO (1) | WO2004002433A1 (xx) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1610797A1 (en) * | 2003-03-27 | 2006-01-04 | Boehringer Ingelheim International GmbH | Antiviral combination of nevirapine and a further antiretroviral compound |
GB0608876D0 (en) | 2006-05-05 | 2006-06-14 | Medivir Ab | Combination therapy |
NZ627826A (en) * | 2010-01-27 | 2016-01-29 | Viiv Healthcare Co | Antiviral combinations involving (3s,11ar)-n-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5446029A (en) * | 1986-07-04 | 1995-08-29 | Medivir Ab | Anti-retroviral activity of 2',3'-dideoxy-3'-fluoronucleosides |
SE8602981D0 (sv) * | 1986-07-04 | 1986-07-04 | Astra Laekemedel Ab | Novel medicinal use |
GB8719877D0 (en) * | 1987-08-22 | 1987-09-30 | Wellcome Found | Antiviral compounds |
NZ229453A (en) * | 1988-06-10 | 1991-08-27 | Univ Minnesota & Southern Rese | A pharmaceutical composition containing purine derivatives with nucleosides such as azt, as antiviral agents |
SE464168B (sv) * | 1989-07-19 | 1991-03-18 | Bo Fredrik Oeberg | Antiviral komposition bestaaende av en 3'-fluoro-2',3'-dideoxynukleosidfoerening och en 2',3'-dideoxynukleosidfoerening (exempelvis azt) |
MY104575A (en) * | 1989-12-22 | 1994-04-30 | The Wellcome Foundation Ltd | Therapeutic nucleosides. |
CA2340156C (en) * | 1998-08-10 | 2007-10-23 | Novirio Pharmaceuticals Limited | .beta.-l-2'-deoxy-nucleosides for the treatment of hepatitis b |
GB9820417D0 (en) * | 1998-09-18 | 1998-11-11 | Glaxo Group Ltd | Antiviral combinations |
MXPA01007359A (es) * | 1999-01-22 | 2003-09-22 | Univ Emory | Beta-d-2', 3'-dideshidro-2', 3`didesoxi-5-fluorocitidina para utilizarla en el tratamiento de infecciones por vih. |
US6514979B1 (en) * | 1999-03-03 | 2003-02-04 | University Of Maryland Biotechnology Institute | Synergistic combinations of guanosine analog reverse transcriptase inhibitors and inosine monophosphate dehydrogenese inhibitors and uses therefor |
WO2001093898A1 (en) * | 2000-06-02 | 2001-12-13 | Smithkline Beecham Corporation | Methods of treating viral diseases with il-18 and il-18 combinations |
-
2003
- 2003-06-24 AU AU2003239088A patent/AU2003239088B2/en not_active Ceased
- 2003-06-24 ES ES03733801T patent/ES2254941T3/es not_active Expired - Lifetime
- 2003-06-24 WO PCT/SE2003/001100 patent/WO2004002433A1/en active IP Right Grant
- 2003-06-24 JP JP2004548906A patent/JP2005533870A/ja active Pending
- 2003-06-24 DE DE60303131T patent/DE60303131T2/de not_active Expired - Fee Related
- 2003-06-24 BR BR0311141-5A patent/BR0311141A/pt not_active IP Right Cessation
- 2003-06-24 RU RU2005101874/15A patent/RU2320347C2/ru not_active IP Right Cessation
- 2003-06-24 PL PL03373758A patent/PL373758A1/xx not_active Application Discontinuation
- 2003-06-24 KR KR10-2004-7021155A patent/KR20050013628A/ko not_active Application Discontinuation
- 2003-06-24 EP EP03733801A patent/EP1536800B1/en not_active Expired - Lifetime
- 2003-06-24 CA CA002481890A patent/CA2481890A1/en not_active Abandoned
- 2003-06-24 US US10/519,332 patent/US20060084627A1/en not_active Abandoned
- 2003-06-24 NZ NZ535817A patent/NZ535817A/en not_active IP Right Cessation
- 2003-06-24 CN CNB038151685A patent/CN1302779C/zh not_active Expired - Fee Related
- 2003-06-24 MX MXPA04012754A patent/MXPA04012754A/es active IP Right Grant
- 2003-06-24 AT AT03733801T patent/ATE314851T1/de not_active IP Right Cessation
-
2004
- 2004-10-28 IL IL16492104A patent/IL164921A0/xx unknown
-
2005
- 2005-01-26 NO NO20050445A patent/NO20050445L/no not_active Application Discontinuation
-
2006
- 2006-01-03 HK HK06100011.9A patent/HK1079981B/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
PL373758A1 (en) | 2005-09-05 |
WO2004002433A1 (en) | 2004-01-08 |
AU2003239088A1 (en) | 2004-01-19 |
MXPA04012754A (es) | 2005-03-23 |
NZ535817A (en) | 2006-11-30 |
US20060084627A1 (en) | 2006-04-20 |
ATE314851T1 (de) | 2006-02-15 |
CN1302779C (zh) | 2007-03-07 |
DE60303131T2 (de) | 2006-07-20 |
AU2003239088B2 (en) | 2006-11-02 |
ES2254941T3 (es) | 2006-06-16 |
WO2004002433A8 (en) | 2004-05-06 |
EP1536800B1 (en) | 2006-01-04 |
NO20050445L (no) | 2005-01-26 |
BR0311141A (pt) | 2005-06-07 |
CA2481890A1 (en) | 2004-01-08 |
EP1536800A1 (en) | 2005-06-08 |
DE60303131D1 (de) | 2006-03-30 |
HK1079981A1 (en) | 2006-04-21 |
RU2320347C2 (ru) | 2008-03-27 |
JP2005533870A (ja) | 2005-11-10 |
CN1665509A (zh) | 2005-09-07 |
RU2005101874A (ru) | 2005-06-27 |
HK1079981B (zh) | 2007-10-12 |
KR20050013628A (ko) | 2005-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR035500A1 (es) | Uso de clorpromazina y pentamidina para la fabricacion de medicamentos, composicion farmaceutica y paquete farmaceutico que comprenden clorpromazina y pentamidina. | |
IL136839A0 (en) | Pharmaceutical compositions comprising cannabidiol derivatives | |
MY125978A (en) | Admantane derivatives | |
MXPA03007712A (es) | Sales farmaceuticas. | |
IL149147A0 (en) | Use of oxcarbazepine for the manufacture of oral dosage form medicament | |
EP1259240B8 (en) | Agents, such as nicotinamide or cadpr for the treatment of skin disorders | |
UY26372A1 (es) | "imidazo-3-il-aminas bicíclicas procedimiento para su preparación y medicamentos que las contienen " | |
TW200600091A (en) | Sulfonylethyl phosphorodiamidates | |
CA2428160A1 (en) | Compositions for antitumor treatment containing ecteinascidin 743 | |
HK1068606A1 (en) | Novel aminobenzoephenones | |
ATE287264T1 (de) | Oral anzuwendende buprenorphinhaltige arzneimittel | |
HRP20041092A2 (en) | New pharmaceutical compositions containing filbanserin polymorph a | |
IL150528A0 (en) | Ibuprofen containing active agent preparation | |
BG108452A (en) | Tablet comprising cetirizine and pseudoephedrine | |
HK1079981A1 (en) | A pharmaceutical preparation comprising a abacavirand alovudine and use thereof | |
AU2003246566A1 (en) | Administration form for the oral administration of active substances, vitamins, and/or nutrients | |
HUP0204208A2 (hu) | Pruritus kezelésére szolgáló külsőleges gyógyszerkészítmény | |
EP1273301A3 (en) | Pharmaceutical preparations based on active ingredients susceptible to illict administration | |
GB2443377A (en) | Anti-malarial composition comprising artesunate and lumefantrine | |
AR109456A2 (es) | Uso de et743 para la preparación de un medicamento para el tratamiento de un paciente humano afectado por cáncer mediante terapia de combinación | |
AU2502301A (en) | Medicament and combination of compatible medicaments | |
AU2002225097A1 (en) | Novel therapeutic use of a thienylcyclohexylamine derivative | |
MXPA03010920A (es) | Uso de alconil l- carnitina para preparacion de medicamento para tratar anhedonia. | |
UA88468C2 (ru) | Сульфонилэтилфосфородиамидаты, предназначенные для применения при лечении рака | |
IL162857A0 (en) | Oral vaccination |